

Catherine Thèves,<sup>1,2</sup> Ph.D.; Christine Keyser-Tracqui,<sup>3</sup> Ph.D.; Eric Crubézy,<sup>2</sup> M.D., Ph.D.; Jean-Pierre Salles,<sup>1</sup> M.D., Ph.D.; Bertrand Ludes,<sup>2,3</sup> M.D., Ph.D.; and Norbert Telmon,<sup>2</sup> M.D., Ph.D.

## Detection and Quantification of the Age-Related Point Mutation A189G in the Human Mitochondrial DNA

**ABSTRACT:** Mutation analysis in the mitochondrial DNA (mtDNA) control region is widely used in population genetic studies as well as in forensic medicine. Among the difficulties linked to the mtDNA analysis, one can find the detection of heteroplasmy, which can be inherited or somatic. Recently, age-related point mutation A189G was described in mtDNA and shown to accumulate with age in muscles. We carried out the detection of this 189 heteroplasmic point mutation using three technologies: automated DNA sequencing, Southern blot hybridization using a digoxigenin-labeled oligonucleotide probe, and peptide nucleic acid (PNA)/real-time PCR combined method on different biological samples. Our results give additional information on the increase in mutation frequency with age in muscle tissue and revealed that the PNA/real-time PCR is a largely more sensitive method than DNA sequencing for heteroplasmy detection. These investigations could be of interest in the detection and interpretation of mtDNA heteroplasmy in anthropological and forensic studies.

**KEYWORDS:** forensic science, mitochondrial DNA, heteroplasmy, age-related mutation, detection methods

The mitochondrial DNA (mtDNA) control region is a hyper-variable sequence widely used in population genetic studies to investigate human evolution, history, and patterns of migration as well as in forensic medicine for individual identification. Among the difficulties linked to mtDNA analysis is the detection of heteroplasmy (the presence of two or more mtDNA types in one individual), which can be inherited or somatic, and sometimes difficult to interpret. In recent years, a number of reports have suggested that during individual natural aging, heteroplasmic point mutations accumulate in the control region of mtDNA of some tissue types (1–4). This accumulation of mutations is thought to be due to the oxidation of DNA bases by free radicals, generated especially during cellular energy production by the mitochondrion (5,6). Among the reported heteroplasmic point mutations, one can find the A to G transition at position 189 (A189G), which has been detected at significant levels in skeletal muscles from aged individuals by several authors (3,4). According to them, the A189G mutation accumulates with age in both healthy subjects and patients with mitochondrial diseases. However, because the level of heteroplasmy is lower in nonpathological cases, the mutation detection is technically difficult and requires a sensitive method (7–9). Moreover, the ratio of mutant (189G) to wild type (189A) has been reported as varying between different tissues from the same individual, which complicates the detection of low proportions of mutant mtDNA (9,10).

In the present study, we searched for the presence of the A189G heteroplasmic mutation in two tissue types, muscle samples and buccal cells, with the following aims: (i) to determine whether the

A189G mutation was really age-related; (ii) to test its presence in buccal cells; (iii) to evaluate the most efficient method for detecting low levels of heteroplasmy; and finally (iv) to assess the possible implications of the A189G heteroplasmy in anthropological and forensic studies.

In order to prove the increase in mutant mtDNA molecules with age, buccal cells were collected from 37 individuals ranging from 4 to 85 years of age and belonging to 10 different maternal lineages. If the A189G mutation accumulates in an age-dependent manner, then it should be present in older subjects but not in younger ones of the same family. We also analyzed muscle samples gathered from 69 subjects 1–97 years of age. These samples were analyzed by means of three technologies: automated DNA sequencing, Southern blot hybridization using a digoxigenin-labeled oligonucleotide probe (11), and peptide nucleic acid (PNA) and quantitative real time PCR (qPCR) together (12,13).

Automated DNA sequencing is a technology widely and routinely used in research and forensic laboratories for population genetic studies or individual identification (14). Southern blot analysis was performed using two probes (with the A or G base at position 189) labeled by a molecule of digoxigenin in 5'. The digoxigenin label can be detected with enzyme-linked immunoassays for antidigoxigenin protein conjugates, and visualized through a chemiluminescent reaction (11). The PNA/qPCR combined method is a less used methodology. The PNA molecule is a DNA mimic, in which the negatively charged sugar-phosphate DNA backbone is replaced by an achiral, neutral polyamide backbone formed by repetitive units of *N*-(2-aminoethyl) glycine (15). The PNA-directed PCR clamping technique has been developed to detect single base-pair mutations (12,16). As shown in Fig. 1, the PNA probe hybridizes perfectly to a target region and prevents PCR primer binding, whereas single base-pair mismatches containing PNA exhibit minimal primer binding inhibition. PNA-directed PCR clamping was used in combination with the real-time PCR (17). The amplification process is monitored in real time by fluorescent dye SYBR Green incorporation and allows a relative

<sup>1</sup>INSERM, U563 Bat C, Purpan University Hospital, Place du Dr Baylac, 31059 Toulouse, France.

<sup>2</sup>Anthropobiologie UMR 8555, 39 allées Jules Guesde, 31000 Toulouse, France.

<sup>3</sup>Molecular Anthropology Laboratory, Department of Forensic Medicine, 11 rue Humann, 67085 Strasbourg, France.

Received 28 July 2005; and in revised form 30 Dec. 2005; accepted 2 Jan. 2006; published 14 June 2006.




FIG. 1—Peptide nucleic acid (PNA)-directed PCR clamping methodology. The arrows show the PCR primers. The bars represent PNA. The asterisks represent mutations. Under appropriate cycling conditions, the PNA will bind to the wild-type, but not to the mutant template, blocking annealing of the upstream primer, and allowing amplification of only the mutant molecules.

quantification of heteroplasmy (13). Unlike other double-strand DNA-selective dyes, SYBR Green is excitable by visible wavelength and provides excellent sensitivity. This method of mutation detection does not require post-PCR manipulations, reducing assay time and the probability of laboratory contaminations.

## Materials and Methods

### Samples and DNA Extraction

Buccal cell samples were collected by a cytobrush on 37 individuals (4–85 years old) who gave their informed consent. Each one of the 10 maternal lineages included two to four members. Buccal samples were incubated for 2 h at 50°C in 400  $\mu$ L extraction buffer (EDTA 5 mM, SDS 2%, Tris HCl 10 mM (pH 7.5), sodium acetate 0.3 M), and 0.2 mg proteinase K. A phenol/chloroform/isooamyl alcohol (25/24/1) extraction was carried out on the supernatant. The aqueous phase was purified with the Cleanmix™ Kit (Talent, Trieste, Italy). After purification, DNA was eluted into sterile water.

Muscle samples (psoas) were collected during forensic autopsies from 69 unrelated individuals ranging from 1 to 97 years in age. Individuals died accidentally and were exempt from any specific disease macroscopically detectable. Approximately 1 cm<sup>3</sup> of muscle fragments were incubated in 3 mL extraction buffer (EDTA 10 mM, NaCl 50 mM, SDS 2%, Tris HCl 10 mM (pH 7.5), and 0.2 mg proteinase K) at 58°C overnight. Total DNA was extracted according to the saturated sodium acetate precipitation method (18). An extraction reagent blank negative control accompanied all muscle and buccal sample extractions throughout the entire analysis.

### Sequencing Analysis

PCR amplification was performed using 1  $\mu$ L total DNA in a 50  $\mu$ L reaction volume containing MgCl<sub>2</sub> 1.5 mM, BSA 0.2 mg/mL, 0.2 mM of dNTPs, primers 200 nM, 1  $\times$  buffer, and 0.5 U of Taq HotGoldstar DNA polymerase (Eurogentec, Seraing, Belgium). The primer sequences are listed in Table 1. Amplification was carried out in a T3 Thermocycler (Biometra, Biolabo Scientific Instruments, Archamps, France). After a 10 min preincubation step at 95°C, PCR amplification was performed by direct PCR

TABLE 1—Sequences of the primers and probes used in this study.

	Sequence (5'–3') by Anderson et al. (20)
Sequencing primer: L29 strand	GGT CTA TCA CCC TAT TAA CCA C
Sequencing primer: H408 strand	CTG TTA AAA GTG CAT ACC GCC A
PNA probe (189 position: A)	CAG GCG AAC ATA CTT
PNA probe (189 position: G)	CAG GCG AGC ATA CTT
Real-time PCR primer: L166 strand	CCT ACG TTC AAT ATT ACA GGC GA
Real-time PCR primer: H253 strand	GTG GAA AGT GGC TGT GCA G
Southern digoxigenin probe (189 position: A)	TAC AGG CGA ACA TAC TTA C
Southern digoxigenin probe (189 position: G)	TAC AGG CGA GCA TAC TTA C
Southern PCR primer: L111 strand	ACC CTA TGT CGC AGT ATC TGT C
Southern PCR primer: H253 strand	GTG GAA AGT GGC TGT GCA G

PNA, peptide nucleic acid.

(35 cycles) using the following conditions: 95°C denaturation for 45 sec, annealing at 53°C for 1 min, and extension at 72°C for 1 min, followed by a 7 min final extension at 72°C. PCR products were analyzed by electrophoresis in 1% agarose low melting (Sigma-Aldrich, St. Quentin Fallavier, France). Purification of amplicon products was carried out on Microcon<sup>®</sup> PCR columns (Millipore, St. Quentin-en-Yvelines, France). Sequencing reactions were performed using the BigDye™ Terminator kit (Applied Biosystems, Courtabeuf, France). The products were purified using the protocol recommended by the manufacturer and submitted to capillary electrophoresis on an ABI Prism 3100 Genetic Analyser (Applied Biosystems). The results were analyzed using the Sequencing Analysis 3.7 Software (PE Applied Biosystems). Negative PCR controls accompanied samples and their extraction reagent blank negative controls throughout the sequencing process.

### PNA Method and Real-Time PCR

PNA sequences and complementary primers for the point mutation A189G are given in Table 1. PNA probes were purchased from Eurogentec. For PNA clamping reactions, PCR reactions contained: SYBR<sup>®</sup> Green Jump Start™ Taq Ready Mix™ (Sigma-Aldrich), 5  $\mu$ L of DNA lysate, 300 nM of each primer, and 2  $\mu$ M PNA probe or H<sub>2</sub>O in 26  $\mu$ L of final volume. The reaction mixture was subjected to a uracil–DNA glycosidase digestion step of 50°C for 2 min (the complex dissociates and the polymerase becomes fully active), followed by 95°C for 10 min and PCR cycling in the ABI Prism<sup>®</sup> 7000 Sequence Detection System (Applied Biosystems). Real-time PCR was run in 40 cycles: denaturation (30 sec at 94°C), PNA hybridization (30 sec at 69°C), primer annealing (30 sec at 60°C), and extension (30 sec at 72°C).

The cycle threshold (*C<sub>t</sub>*) value is defined by the cycle at which SYBR<sup>®</sup> Green fluorescence increases significantly above the background as a result of specific amplification. *C<sub>t</sub>* values were calculated by extrapolation to the *x* axis of the linear portion of the exponential growth phase. The reported *C<sub>t</sub>* is the cycle number adjoining the *x* intercept (19).

Preliminary optimization and validation of the PNA/qPCR combined method were carried out on two muscle DNA extracts. These samples (controls) were previously sequenced and identified as A (wild-type = WT) or G (mutant = M) at position 189.

Linearity of template amplification relative to copy number was demonstrated. PCR efficiency ( $E$ ) was calculated according to the equation:  $E = 10^{(-1/\text{slope})}$  and showed a PCR efficiency of 1.14. A dissociation protocol (Applied Biosystems) was performed, in order to identify the amplicon according to its melting temperature. Then, a melting curve analysis confirmed the amplification of a single product with a specific melting temperature of 75°C.

#### Relative Quantification

A scale of G variant from 0 to 100 obtained by mixing in equimolar proportions DNA from M and WT controls established an experimental reference curve. In a first run, 11 points (in the following percentages: 0%, 10%, 20%, ..., 90%, and 100%) were evaluated and amplification was repeated three times for each condition: without a PNA probe, with a PNA G probe, or with a PNA A probe (Table 1). Average amplification cycles were established for each point and an intra-assay precision test was calculated (19). A second run was conducted including extra points situated between 0% and 20% and between 80% and 100% of the G variant. Then, the points common to each run enabled us to calculate an interassay precision test (19).

Once this experimental curve was established ( $x = \text{mutant } \%$ ;  $y = G/A C_t$  ratio), the Statistica v5.1 computer software (StatSoft, Tulsa, OK) calculated the percentage of mutants by its inverse relationship ( $x = G/A C_t$  ratio;  $y = \text{mutant } \%$ ).

For each sample on the same run, an amplification triplicate was conducted for each PCR condition (without PNA probe, with PNA G probe, or with PNA A probe). The  $C_t$  obtained ( $C_t A$  for PNA A probe and  $C_t G$  for PNA G probe) was used to calculate the level of variant G or A present in the sample's mtDNA. A blank amplification as well as two M and WT controls were systematically included for each run.

#### Southern Blot

A 2- $\mu$ L DNA was amplified by using primers the listed in Table 1. PCR conditions were performed using a DNA thermal cycler (Perkin Elmer 2400) in a 26- $\mu$ L reaction volume containing  $MgCl_2$  1.5 mM, dNTPs 200 nM, 400 nM of each primer, buffer  $1 \times$ , and 1 U of Taq polymerase (Promega, Madison, WI). PCR steps were determined with an initial denaturation step at 94°C for 1 min, followed by 35 cycles including a denaturation step for 15 sec at 94°C, a hybridization step for 30 sec at 57°C, an extension step for 45 sec at 72°C, and a final extension step for 2 min at 72°C.

Southern blot was performed using standard techniques. PCR products were blotted onto membranes (immobilon<sup>TM</sup> NY+, Millipore, Bedford, MA) and hybridized with 5'-digoxigenin-labeled probes (Eurogentec) (Table 1). Detection of the digoxigenin-labeled hybridized probes was performed using the DIG Luminescent Detection Kit as described by the manufacturer (Roche Applied, Penzberg, Germany). Detection of 5'-digoxigenin probes was performed by exposure to an X-ray film and analyzed using ImageQuant software v1.1 (Molecular Dynamics).

## Results

#### Automated DNA Sequencing

All samples were initially analyzed by automated DNA sequencing. The region studied at position 189 is highly polymorphic, for example at sites 182 or 195. The probes (for the PNA or Southern blot techniques) were synthesized on 15 or 20 bases ac-

TABLE 2—Polymorphism characterization in the hybridization region of PNA probes.

	1	1	1	1	1	1
Cambridge	8	8	8	8	8	9
Sequence by	2	4	5	8	9	5
Anderson et al. (20)	C	G	G	A	A	T
Muscle samples	7	.	.	.	.	C
	1	.	.	.	G	C
	1	T	.	.	.	.
	2	.	.	A	G	.
	1	.	.	A	.	.
	1	T	.	C	.	C
Buccal samples	6	.	.	.	G	.
	1	.	.	.	.	C
	2	T	A	.	.	.
	6	.	.	A	G	.

PNA, peptide nucleic acid.

ording to the Cambridge Sequence (20) with a variation of bases A and G at position 189 (Table 1). It is necessary to know the samples' sequences underlying the probe in order to select the samples with the complementary *Cambridge Sequence*.

Of the 69 muscle samples studied, 13 were polymorphic between positions 182 and 195 and could not be analyzed by the PNA/qPCR or Southern blot methods. Their sequences were not complementary to those of the probes. Among the 13 polymorphic samples (Table 2), nine were situated at the extremity of the probe (195 or 182) and four in a more central position (185 or 188). Among all samples analyzed by sequencing, 11 (belonging to individuals of 38–97 years of age) had an A/G heteroplasmy at position 189 (Table 3). Among the 11 heteroplasmies detected, two individuals aged 68 and 77 years old also had a polymorphism at position 195, and could not be analyzed by the different methods using probes.

The 37 buccal samples from individuals of 4–85 years of age were also analyzed by automated DNA sequencing. For six of them (belonging to two families of different maternal lineage), we were able to identify G at position 189 (Table 2); this transition was considered transmitted as it was found in all members of the family. Other polymorphisms were revealed by this sequencing method (Table 2) and located either at the end or in the central part of the probe's hybridization region. Collection of buccal samples was carried out by family grouping; polymorphism detection excluded several families (representing a total of 14 individuals) from the PNA/qPCR or Southern Blot analysis. No A189G heteroplasmy was detected in any of the 37 buccal samples with sequencing (Table 3).

In order to determine the threshold of the automated DNA sequencing method, the experimental variant G scale was tested by this technique. A sequencing pattern G peak at position 189 was detectable for minimum 30% of G variants.

#### PNA/qPCR Tests

To test the linearity of the probe's PCR clamping according to the DNA concentration, serial dilutions were performed between 100 and 0.001 ng from total DNA of WT and M controls. Differences in  $C_t$  ( $\Delta C_t$ ) between amplification with or without PNA were constant for total DNA concentrations between 100 and 0.1 ng. Initial amplification of each sample without probe had to be included between 16 and 26  $C_t$ . If the DNA concentration or quality was low, the samples could not be analyzed because they were outside the linearity of the probe's PCR clamping. For this

TABLE 3—Characterization of position 189 between three technologies on muscle tissues and buccal cells.

Samples	n	Automated Sequencing		PNA/qPCR Method		Southern Blot	
		n	A189G Heteroplasmy	n	A189G Heteroplasmy	n	A189G Heteroplasmy
Muscle tissues	69	69	11	50	44	50	27
Buccal cells	37	37	0	23	18	23	0

The PNA/qPCR method allowed detection of low levels of the A189G heteroplasmy in two cell types. The automated DNA sequencing did not detect the heteroplasmy level inferior to 30%. In buccal cells, heteroplasmy was globally inferior to 10% and was not detected by automated sequencing or by Southern blot. In muscle samples, Southern blot detected heteroplasmy level superior to 10% and the PNA/qPCR method could determine all levels of heteroplasmy.

PNA, peptide nucleic acid; qPCR, quantitative real-time PCR.

reason, five muscle samples were excluded from the PNA/qPCR analysis.

To test the efficiency of the PCR clamping according to the percentage of mutants present in total mtDNA, we produced variant G ratios from WT and M controls. We tested both PNA probes during qPCR amplifications (Fig. 2a and b). Each graph demonstrated that the curves between the proportion of mutants

and the PCR clamping were exponential and had inverse relationships. The  $C_t$  values included between 0% and 80% of G variant for the PNA G probe (Fig. 2a) and between 20% and 100% for the PNA A probe (Fig. 2b) varied only slightly. The differences between the  $C_t$  values with and without the PNA probe ( $\Delta C_t$ ) were noticeable only between 80% and 100% of mutants for the PNA G probe (Fig. 2a) and between 0% and 20% for the PNA A probe (Fig. 2b). Finally, the use of only one probe would only have enabled us to analyze levels of mutants  $\leq$  or  $\geq$  80% of variant G for the PNA G probe and levels of mutants  $\leq$  or  $\geq$  20% of variant G for the PNA A probe. However, in order to obtain opposite and complementary  $C_t$  values between both PNA probes, the level of G variant had to be located between 0% and 20% or 80 and 100%. From the  $C_t$  ratio G/A, we established a variant G reference curve, to estimate the level of mutation in a more precise manner. Figure 2c demonstrates that the G/A  $C_t$  values led to a better resolution of the mutant levels between 20% and 80%.

#### Intra-assay and Interassay Precision Tests

Amplification triplicates were conducted on the same run and for each different condition (without a PNA probe and with a PNA G or A probe) to test the precision of the variant G curve. As suggested by the manufacturer (Applied Biosystems), a value  $\leq 0.5 C_t$  was considered to be acceptable between triplicates of the same experimental condition in a same run. Also, the intra-assay precision test values on WT and M controls in each of the three PCR conditions were situated between 0.1% and 0.5% (19). The test's precision on two runs for two different days, representing two triplicates for each control condition, was also measured. The interassay precision test was situated between 1.5% and 4.4% for the three PCR conditions (19).

The experimental reference curve of the controls' G/A values (Fig. 2c) was reversed in order to obtain an estimated level of mutants in an unknown sample. We have excluded 0% and 100% points in this inverse relationship and their corresponding G/A




FIG. 2—(a) Amplification depending on the percentage of mutants (189G variant) with the PNA G probe. Estimation of the percentage of mutants given by the  $C_t$  difference between the amplifications with or without a PNA G probe ( $C_t$  G) was noticeable in values  $< 80\%$ , or  $> 80\%$  of G variant. (b) Amplification depending on the percentage of mutants (189G variant) with a PNA A probe. Estimation of the percentage of mutants given by the  $C_t$  difference between the amplifications with or without a PNA A probe ( $C_t$  A) was noticeable in values  $< 20\%$ , or  $> 20\%$  of G variant. (c) The  $C_t$  value ratio of PNA G probes on PNA A probes depending on the percentage of mutants (189G variant.) The  $C_t$  value ratio of PNA G probe on PNA A probe led to a better resolution of the G variant level in the 20% to 80% interval.  $\blacklozenge$ , G mutant cycle threshold ( $C_t$ ) values with peptide nucleic acid (PNA) probe;  $\blacksquare$ , wild-type (WT) and mutant (M) controls  $C_t$  values without PNA probe.




FIG. 3—Percentage of 189G mutants estimated by the G/A cycle threshold ( $C_t$ ) values ratio.  $X = G/A C_t$  values ratio;  $Y = 189 G$  mutant percentage. From Fig. 2c and the analysis by Statistica 5.1 software, the inverse polynomial function was established ( $y = -2737.2 + 11,918x - 19,242.5x^2 + 13,574.1x^3 - 3486.6x^4$ ). It calculated the level of mutants present in a sample by its G/A  $C_t$  ratio.

$C_t$  ratios (0.7 for 0% and 1.6 for 100%) because they lacked complementary information. Statistica v5.1 software calculated a polynomial function (Fig. 3) from measured G/A  $C_t$  ratios, and the values of mutant levels were obtained with a 1.4% average standard deviation (SD) (minimum SD: 0.02%, maximum SD:




FIG. 4—(a) Accumulation in buccal cells of the A189G heteroplasmy level with age ( $n = 23$ ). The level of 189G mutants was determined by the G/A cycle threshold ( $C_t$ ) ratio within the peptide nucleic acid (PNA)/real-time PCR run. None of the G/A  $C_t$  ratios measured surpassed 0.92, thus giving a maximum percentage estimation of G variants of 12.6%. (b) A189G heteroplasmy in buccal cells of individuals belonging to the same maternal lineage (from three different families). Mutation 189G in levels inferior to 12.6% was detected in subjects of the same family by PNA/qPCR. Mutation was absent or weakly present in the younger individuals compared with the older ones of the same family.




FIG. 5—Accumulation in muscle samples of the A189G heteroplasmy with age. The level of 189G mutants was determined by the G/A cycle threshold ( $C_t$ ) ratio within the peptide nucleic acid (PNA)/real-time PCR run. After 50 years of age, the levels are generally  $\geq 10\%$  (15/19); for those 60 years old or more, the levels are closer to 20% and over (10/12). The individuals 40 years old or less, except a few individuals (5/23), have levels of mutations  $\leq 10\%$ .

4.1%). The function was then applied to the  $C_t$  G/A ratios of the samples.

*PNA/qPCR Samples*

In order to be statistically representative, a minimum variation of  $\leq 0.5 C_t$  was considered to be acceptable for all amplification triplicates of a given condition. The intra-assay precision test carried out on both tissue types was between 0.06% and 1.68% (19). Samples presenting unstable amplification in a run were either reanalyzed or excluded.

Among the 23 buccal samples analyzed by the PNA/qPCR method, 18 presented a level of heteroplasmy at position 189 superior to 5%, the maximum being 12.6% (Fig. 4a). These heteroplasmy levels were especially noticeable in three of four members (4, 37, 60, and 85 years old) of the same maternal lineage (Fig. 4b; family 1). While the heteroplasmy mutation was detected in the three adults (at levels of 8–9.5%), it was not observed for the child. Similarly, the heteroplasmy mutation was detected in the older members (73 and 80 years old at levels of 12.6% and 11.5%, respectively) in families 2 and 4, and more slightly observed in the younger members (at levels of 1.5–8.9%) (Fig. 4b). From these family observations, even though the level of mutation was low, we noticed that the A189G transition in its heteroplasmy form was a somatic mutation because it was less or not observed in young individuals. Considering all the individuals (Fig. 4a), heteroplasmy levels were low and there did not seem to be an accumulation threshold age for this specific mutation.

The 50 muscle samples from individuals of 1 to 97 years old were analyzed by the PNA/qPCR method. Figure 5 represents the accumulation of the 189G mutation according to the subject's age. The levels of heteroplasmy were higher in the muscle tissues compared with the buccal samples. In fact, for individuals 60 years old or more, the level of mutants was  $\geq 20\%$  for 10 out of 12 individuals (against 12.6% for buccal cells). In contrast, for individuals less than 40 years old, the percentage of mutants was low:  $\leq 10\%$  for 18 of the 23 individuals analyzed. The PNA/qPCR method also detected the 189G polymorphisms identified in the six buccal samples by sequencing (Table 2). As expected, the G/A  $C_t$  values were similar to the control M (i.e.,  $\geq 1.6$ ).




FIG. 6—(a) Detection of the heteroplasmy A and G in position 189 in muscle samples of individuals more than 60 years of age. The M probe (189G) showed clear evidence of 189G variants on muscle tissues of individuals more than 60 years of age. The percentage of mutations is of 20% or more in all individuals except for a 77-year-old individual whose level was low ( $\leq 5\%$ ). (b) Detection of the heteroplasmy A and G in position 189 in muscle samples of individuals less than 60 years of age. The M probe (189G) showed levels of 189G mutants  $\geq 10\%$ . These levels were found in most of the individuals more than 50 years of age (5/7). For those 40 years old or less, the percentage of mutation was  $\leq 10\%$  (18/23) and was barely detected or undetected by Southern blot. (c) Detection of the heteroplasmy A and G in position 189 in double sampling (muscle tissue and buccal cells) from two individuals. The M probe (189G) revealed the tissue variability of the 189G heteroplasmy. In the muscle tissue, evaluation of the percentage of mutants by ImageQuant software was 12% for the 63-year-old individual and 20% for the 70-year-old. Detection of the 189G heteroplasmy in buccal cells was very weak and relative quantification estimated the percentage of G mutants to be  $\leq 5\%$ . Southern blot. WT, wild-type control; M, mutant control; the samples were classified by age; m, muscle tissue; b, buccal cells.

#### Southern Blot

All buccal and muscle samples with the complementary Cambridge Sequence to the probe's hybridization region were analyzed by Southern blot. The detection of the 189G heteroplasmic form in muscle tissues was important in individuals more than 60 years old (Fig. 6a). The labeling's relative quantification was performed by the ImageQuant software and the percentage of mutants detected in the samples was calculated compared with M control (an equal quantity of control or samples DNA was deposited). Concerning the individuals below 60 years old (Fig. 6b), with a lower percentage of G variants, detection was lesser but present up to 40 years of age. Individuals less than 40 years old (with a few exceptions) were lightly or not labeled. The method's detection limit of the percentage of G variant seemed to be 10%. In the 50 muscle samples analyzed by the Southern blot method, detection of the 189G heteroplasmic form was demonstrated in 27 individuals in levels close to 10% and quantified by the ImageQuant software (Table 3). In contrast, detection of mutant molecules was almost impossible in buccal cells and did not allow sample discrimination.

Moreover, we obtained from two deceased individuals, 63 and 70 years old, both types of tissue samples and as shown in Fig. 6c, the 189G heteroplasmy was clearly detected in the muscle tissues of each one of them (with a percentage of 12% and 22%, respectively) and was slightly present in buccal cells ( $\leq 5\%$ ).

#### Discussion

In order to minimize possible contaminations, which can be disastrous in the research of heteroplasmy, negative controls were performed at each of our method's steps (extraction, PCR, sequencing, real-time PCR). Our laboratory followed the working conditions suggested by the EDNAP group in order to prevent any possible contamination (21). Pre- and post-PCR areas were separated and all disposables were treated by UV cross-linking. Concerning the sequencing method, samples were analyzed on both their DNA strands to confirm heteroplasmy. They were analyzed only when both bases appeared visible above the background and on both strands. A positive control as well as the laboratory personnel's sequence were determined in order to test the absence of sample contamination. Our DNA samples were of good quality and their amount was sufficient for a good PCR amplification. This is why the number of PCR cycles was limited to 35 for the initial PCR amplification of the specific strand before its analysis by sequencing. Concerning the three detection methods, all PCRs were conducted with a number of cycles between 35 and 40. Indeed, when the amount of DNA is low, the number of cycles needs to be increased, for example in hair mtDNA analysis, and heteroplasmic artifacts should occur (22). The five muscle samples whose amplification occurred late by the PNA/qPCR method ( $C_t$  without probe was over 30) were excluded from our study because they were not situated within the linearity of the PCR clamping. Consequently, the levels of heteroplasmy found on our healthy muscle samples were similar to those published previously (4). We also excluded from our studies individuals whose autopsies revealed any mitochondrial or neurodegenerative pathologies. The muscle samples all came from the psoas, a muscle with low energetic needs on working or living conditions. Among the individuals chosen for the buccal samples, none presented pathologies linked with oxidative stress.

Analysis by sequencing of PNA probes hybridization region polymorphism enabled us to evaluate the effects of these polymorphisms on the PNA/qPCR method. The PNA probe's sequence mismatch leads to instability and an important loss in the probe's hybridization temperature. Loss in hybridization temperature is more or less important depending on the mismatched base and its location in the probe's sequence (16).

If the mismatch is central, the instability is the greatest and the hybridization temperature can increase up to  $15^\circ\text{C}$ . We decided to locate the nucleotides A and G at position 189 in the center of the probe so that an eventual mismatch could lead to a significant temperature loss. However, when the mismatch occurs near the probe's extremities, temperature loss is less significant (around  $7^\circ\text{C}$  or  $8^\circ\text{C}$ ) and primer or PNA hybridization can take place in various proportions independently of the base at position 189. This kind of probe or primer hybridization can be observed in polymorphic samples near the extremities of the PNA probes and can lead to important  $C_t$  variations during real-time PCR cycles. Such polymorphic samples presented higher  $C_t$  variations than the accepted value ( $0.5 C_t$ ) between triplicates of the same run. Consequently, we could not take into consideration the polymorphic samples'  $C_t$  values. Concerning the samples containing central polymorphisms (e.g., positions 185 or 188), the amplification result was different. Whatever the PNA probe, the mismatch occurred systematically because of the central polymorphism leading to a significant loss in hybridization temperature. With or without a PNA probe, the amplification varied slightly ( $\leq 1 C_t$ ).

It is interesting to notice that two polymorphic samples in the position 195 had a heteroplasmy in position 189 detectable by sequencing, in rates higher than 30%, and were from individuals 77 and 68 years old. In order to analyze them completely, and samples where heteroplasmy was not detected by the sequencing method, we would need to synthesize PNA probes whose sequence would correspond to the most common polymorphisms. Among all our samples (muscle and buccal), 195 and 188/185 positions are the most polymorphic sites.

Comparison of automated sequencing and PNA/qPCR methods demonstrated two facts. Where the levels of 189G mutant molecules were >30%, including nine muscle samples submitted to both techniques, the percentage of G variants obtained, either by the peak heights on the sequencing pattern or by the qPCR's  $C_i$  G/A ratio, was the same. This observation revealed that our evaluation method was correct if certain precautions like minimal variations between same-sample triplicates ( $\leq 0.5 C_i$ ) were respected and if a standard deviation of 1.4% was included. Concerning the lower levels of heteroplasmy, our study demonstrated that the PNA/qPCR method was more sensitive. In fact, 44 muscle samples were identified as heteroplasmic in position 189, when only nine were detected in the older individuals by automated sequencing (Table 3).

This sensitive difference between sequencing and PNA/qPCR methods incited us to use a third detection method, the Southern blot, in order to evaluate and confirm the previously detected heteroplasmy by the PNA/qPCR method. The Southern blot method confirmed the PNA/qPCR results in detecting levels of heteroplasmy as low as 10%. As shown in Fig. 6a and b, among individuals of 40 years old or more, this technique detected the 189G form of heteroplasmy in proportions of 50–10%. Moreover, the relative quantification of the labeling by the probe on mutants using ImageQuant software confirmed the proportion of mutant levels analyzed through both methods. For example, in Fig. 6a, individuals 87 and 74 years old had an estimated percentage of mutants, respectively, of 44% and 21%, whereas the 77-year-old individual's labeling was estimated at 1% (considerably under this technique's level of detection). The estimated percentage of G variants with the PNA/qPCR method on these same individuals was 48% for the 87-year-old, 19.7% for the 74-year-old, and 5.3% for the 77-year-old. This was also true for lower levels as shown in Fig. 6b where the 43-year-old individual presented a Southern blot labeling of 15.5% with the M probe and of 13.2% with the PNA/qPCR method.

However, concerning the buccal samples, the Southern blot technique did not reveal the really low heteroplasmy levels detected by the PNA/qPCR technique, because the variant G rates remained very low in buccal cells with a maximum of 12.6%. As shown in families 2 and 4 (Fig. 4b), the 73- and 80-year-old individuals represented an estimated 12.6% and 11.5% of mutants with the PNA/qPCR method, these individuals showed a very weak labeling with the Southern blot technique, estimated  $\leq 5\%$  by the ImageQuant software. The difference in detection can be explained by the detection limits of the Southern blot technique, but also by an estimated percentage of errors of the PNA/qPCR technique and/or experimental differences.

Our study exerts another important fact: the accumulation of mutations is higher in skeletal muscle (20–50% in the older individuals) than in buccal cells (12.6% maximum) (Figs. 4a and 5). These high mutation levels in muscle tissue have been described previously (3,4). This difference could be explained by the important mitotic activity in buccal cells. mtDNA mutations, associated with aging, are frequently found to accumulate themselves

rapidly in tissues with high energetic needs and slow mitotic activity, like skeletal muscle, heart, and brain (6,23,24). This could explain why the mutation level in buccal cells did not have an accumulation threshold age (Fig. 4a) and why the variation in mutation percentage between a 40-year-old individual and a 60-year-old one cannot be found, because the rapid cell turn-over could conceal the mutation accumulation. Therefore, even in advanced ages (three individuals were over 80 years old among the buccal samples), the mutation level did not exceed 10%, cellular turn-over overcoming the cumulating mutational process.

The fact that the A189G mutation accumulates itself in a tissue-specific manner is clearly established by double sampling on two individuals (of 70 and 63 years old). For both, we collected muscle and buccal samples and analyzed them by the PNA/qPCR method. Concerning the 70 year old, the percentage of mutant molecules was 8.9% in buccal cells and 21.2% in muscle tissue. A similar situation was observed for the 63-year-old as the level of mutant was 3.5 times higher in muscle tissues than in buccal cells (3.9% vs. 14.3%). These results were confirmed by the Southern blot method (Fig. 6c) where the 70-year-old individual presented a higher labeling level in muscle tissue than in buccal cells. This was also confirmed by ImageQuant software; the level of mutation in muscle tissue was 22% compared with buccal cells where it was  $\leq 5\%$ . The variation in the mutation frequency between different tissues has been previously established in mitochondrial pathologies (10), implying once again the cellular turn-over.

The simultaneous use of three technologies in our work, besides demonstrating better sensitivity of the PNA/qPCR method, revealed an interesting technical point. Automated DNA sequencing is a widely used technique to detect mtDNA mutations; nevertheless, it has been demonstrated by serial dilution experiments that low levels ( $\leq 20\%$ ) of mtDNA heteroplasmy could not be reliably detected by this technique (25). In this study, we also showed that automated DNA sequencing did not allow a quantitative estimation of the proportion of A189G mutations <30%. This technique usually uses dye-labeled terminators, which are dideoxynucleotide triphosphates (ddNTPS) labeled with different fluorophores (26). A major drawback of the dye-terminator chemistry is the highly uneven peak pattern produced after the amplification reaction, the latter being largely dependent on the local sequence context and the DNA polymerase used (27). Dideoxynucleotides labeled with BigDye™ Terminator show more uniform peak heights and less G suppressions (14). However, Zakeri et al. (28) have analyzed the context dependency of peak height variations to improve data interpretations. A common problem occurs when a G follows an A. The size of dye-labeled G peaks was lower than the height of the preceding A peak in the sequencing pattern. This was true for sites of mixed A/G bases in heterozygous mutations (29). This variability in peak height reduced the base-calling accuracy of software and hindered heterozygous mutation detection. In the case of the 189 position, where the local sequence was either GAA or GAG, the G BigDye™ Terminator was incorporated with difficulties in comparison with the A BigDye™ Terminator, giving rise to an A peak with an underlying G peak in this sequence. These problems, low levels of heteroplasmy and G BigDye™ incorporation after or with A BigDye™, could explain detection differences between automated sequencing and the PNA/qPCR method as well as the differences in detection levels of 20% for Chinnery et al. (25) and of 30% in our study.

An early study already demonstrated difficulties in detecting heteroplasmy according to the different techniques used (30). The sensitive denaturing gradient-gel electrophoresis (DGGE)

revealed heteroplasmy detection at levels as low as 1%. This way, the mtDNA heteroplasmy frequency was more common in comparison with those reported by sequencing analysis. Very recently, Hancock et al. (31) evaluated the sensitivity of other detection techniques. Particularly, the automated DNA sequencing, including several chemistries and genetic analyzers, allowed detection at 30% levels. At 20% or 10%, the heteroplasmy was difficult to distinguish from the baseline noise, and was detectable only if the position was known. In contrast, the PNA technique was able to detect the mutation at the 5% level.

As seen in our work, the PNA-directed PCR clamping technique is a very specific and highly sensitive method to identify single nucleotide changes in DNA molecules (12). According to Murdock's team, it allowed the detection of mutant molecules at a level of 1% of total molecules by direct PCR (2,32). Individual nucleotide bases are attached to each peptide unit to provide a molecular design that enables PNA to hybridize to complementary nucleic acid targets according to the Watson and Crick base-pairing rules (33). PNA-DNA hybrids are more stable than DNA-DNA hybrids and PNA hybridization kinetics is less influenced by sodium concentration. PNAs are more sensitive to internal base-pair mismatch with their DNA complement; this can result in a 10 to 18°C lower melting temperature. Moreover, PNA is not recognized by polymerases and therefore cannot be copied or used as a primer. PNA probes are more robust detector molecules for real-time PCR methods than many of their DNA-derived counterparts, such as the hybridization probes, which are degraded during PCR by the endonuclease activity of Taq DNA polymerase (34). This technique, combined with real-time PCR, allowed a very sensitive quantification and an excellent reproducibility.

The PNA/qPCR sensitivity and accuracy compared with that of automated DNA sequencing could be interesting in forensic investigations where detection of heteroplasmy is not unusual. Technically, the advantage of the PNA/qPCR method is that it requires very few pre-PCR manipulations and no post-PCR. One run including amplifications without and with both probes is enough to obtain fast and reliable results on the level of heteroplasmy in a sample with minimum contamination possibilities. In order to limit the lack of precision, we can incorporate both WT and M controls into the run but also the experimental scale of G variant on the samples amplification run, adding internal precision to the method with a limited margin of error. It is nonetheless necessary to know ahead of time the studied samples' sequences in order to apply the corresponding PNA probe for the 189 position. Other age-related heteroplasmies have been described at positions 414 and 408 (1,2,4); their investigation could benefit from this technique and their hybridization region is less polymorphic sites requiring only two PNA probes. The PNA/qPCR method is rapid and flexible, avoids laboratory contaminations by limiting the number of manipulations, and enables a fine detection in levels  $\leq 10\%$ .

Moreover, the fact that the level of heteroplasmy varies in the different tissues of an individual, and that it can be expressed at very low levels in some (i.e., buccal cells vs. muscle tissue) increases interpretation difficulties. This is where a very sensitive method can be used to obtain very low levels of detection. Interpretation in forensic cases can sometimes be complicated because of the presence of heteroplasmies in the given sample (e.g., hair) and of its absence in others (e.g., blood). Consequently, demonstrating the presence of mutant molecules in two different samples can help eliminate uncertainties. In contrast, if the number of mutants is higher in the muscle samples, other tissue samples should be preferred (like buccal cells or blood) for automated

mtDNA sequencing in forensic cases to minimize interpretation uncertainties.

Because a correlation was clearly established between the age of the studied individual and the level of mutant molecules at position 189, the age of the subject tested should be considered when interpreting mtDNA typing results. As previously underlined by Calloway et al. (9), age and heteroplasmy should be considered in missing person cases when a significantly older individual is used as a reference for a missing younger maternal relative. In the same way, this information is useful for interpretation of mtDNA case-works including mass disaster biological remains.

It is obvious, as shown in Fig. 5, that evaluating only one heteroplasmic mutation point cannot help determine the analyzed individual's age and this was not the aim of this study. Nonetheless, we could suggest evaluating several heteroplasmic mutation points and/or mitochondrial deletions. In fact, mitochondrial deletions accumulate with age, and were quantified using real-time PCR by von Wurmb-Schwark et al. (35). Counter-crossing the values of several heteroplasmic mutation points or deletions could help recognize these age-related mutations in relation to human aging. We should also investigate a possible link between these mutations and osteologic markers of normal and pathological aging widely used in forensic medicine, increasing label performances in identification cases.

## Conclusion

The analysis of heteroplasmic A189G mutation by the PNA/qPCR method permitted a sensitive detection as well as reliable and reproducible quantification of mutant level. This technique allowed us to demonstrate the absence of the A189G transition in buccal cells in young individuals and its presence in older individuals from the same maternal lineage, concluding that it is a somatic mutation. Moreover, we demonstrated for the first time the accumulation with age of the A189G mutation in mitotic buccal cells in levels lower than 13%. In postmitotic muscle tissues, mutation accumulation was age-related and reached very high levels in individuals 60 years of age or older. Our results could have many implications in heteroplasmy interpretation in forensic caseworks but also in anthropological studies, for example in the investigations of great names of history.

## Acknowledgments

We are grateful to Pr. D. Rouge and B. Martinez (Service de Médecine Légale de Rangueil, Toulouse) for the access to muscle tissue materials.

We would like to thank S. Romac (Laboratoire d'Anthropologie Moléculaire, Strasbourg) for technical help, C. Cariven and N. Malet (INSERM U563, Toulouse) for technical advices, and S. Laurencin for helpful English writing.

Grant Sponsor: ACI "Espaces et Territoires: le Complexe Spatial Altaï-Baïkal. Plaque tournante des flux géniques en Haute Asie de la période protohistorique à l'époque moderne"

## References

1. Michikawa Y, Mazzucchelli F, Bresolin N, Scarlato G, Attardi G. Aging-dependent large accumulation of point mutations in the human mtDNA control region for replication. *Science* 1999;286:774-9.
2. Murdock DG, Christacos NC, Wallace DC. The age-related accumulation of mitochondrial DNA control region mutation in muscle, but no brain, detected by a sensitive PNA-directed PCR clamping based method. *Nucleic Acids Res* 2000;28(21):4350-5.

3. Wang Y, Michikawa Y, Mallidis C, Bai Y, Woodhouse L, Yarasheski KE, et al. Muscle-specific mutations accumulate with aging in critical human mtDNA control sites for replication. *Proc Natl Acad Sci USA* 2001;98(7):4022–7.
4. Del Bo R, Bordoni A, Boneschi FM, Crimi M, Sciacco M, Bresolin N, et al. Evidence and age-related distribution of mtDNA D-loop point mutations in skeletal muscle from healthy subjects and mitochondria patients. *J Neurol Sci* 2002;202(1–2):85–91.
5. Harman D. The biologic clock: the mitochondria? *J Am Geriatr Soc* 1972;20(4):145–7.
6. Linnane AW, Marzuki S, Ozawa T, Tanaka M. Mitochondrial DNA mutations as an important contributor to ageing and degenerative diseases. *Lancet* 1989;1:642–5.
7. Jazin EE, Cavelier L, Eriksson I, Orelund L, Gyllensten U. Human brain contains high levels of heteroplasmy in the noncoding regions of mitochondrial DNA. *Proc Natl Acad Sci USA* 1996;93:12382–7.
8. Wilson MR, Polansky D, Replogle J, Di Zinno JA, Budowle B. A family exhibiting heteroplasmy in the human mitochondrial DNA control region reveals both somatic mosaicism and pronounced segregation of mitotypes. *Hum Genet* 1997;100:167–71.
9. Calloway CD, Reynolds RL, Herrin GL Jr, Anderson WW. The frequency of heteroplasmy in the HVII region of mtDNA differs across tissue types and increases with age. *Am J Hum Genet* 2000;66:1384–97.
10. Chinnery PF, Zwijnenburg PJG, Walker M, Howell N, Taylor RW, Lightowlers RN, et al. Nonrandom tissue distribution of mutant DNA. *Am J Med Gen* 1999;85:498–501.
11. Holtke HJ, Ankenbauer W, Muhlegger K, Rein R, Sagner G, Seibl R, et al. The digoxigenin (DIG) system for non-radioactive labelling and detection of nucleic acids – an overview. *Cell Mol Biol* 1995;41(7):883–905.
12. Ørum H. PCR clamping. *Curr Issues Mol Biol* 2000;2(1):27–30.
13. Kyger EM, Krevolin MD, Powell MJ. Detection of the hereditary hemochromatosis gene mutation by Real-Time fluorescence polymerase chain reaction and peptide nucleic acid clamping. *Anal Biochem* 1998;260:142–8.
14. Rosenblum BB, Lee LG, Spurgeon LG, Khan SH, Menchen SM, Heiner CR, et al. New dye-labeled terminators for improved DNA sequencing patterns. *Nucleic Acids Res* 1997;25(22):4500–4.
15. Nielsen PE, Elghom M, Buchardt O. Peptide nucleic acid (PNA), a DNA mimic with a peptide backbone. *Bioconjugate Chem* 1994;5:3–7.
16. Ørum H, Nielsen PE, Elghom M, Berg RH, Buchardt O, Stanley C. Single base pair mutation analysis by PNA directed PCR clamping. *Nucleic Acids Res* 1993;21(23):5332–6.
17. Wittwer CT, Herrmann MG, Moss AA, Rasmussen RP. Continuous fluorescence monitoring of rapid cycle DNA amplification. *Biotechniques* 1997;22:130–8.
18. Cattaneo C, Smillie DM, Gelsthorpe K, Piccinini A, Gelsthorpe AR, Sokol RJ. A simple method for extracting DNA from old skeletal material. *Forensic Sci Int* 1995;74:167–74.
19. Gibson UEM, Heid CA, Williams MP. A novel method for Real Time Quantitative RT-PCR. *Genome Res* 1996;6:995–1001.
20. Anderson S, Bankier AT, Barrell BG, de Bruijn MHL, Coulson AR, Drouin J, et al. Sequence and organization of the human mitochondrial genome. *Nature* 1981;290:457–65.
21. Tully G, Bar W, Brinkmann B, Carracedo A, Gill P, Morling N, et al. Considerations by the European DNA profiling (EDNAP) group on the working practices, nomenclatures and interpretation of mitochondrial DNA profiles. *Forensic Sci Int* 2001;124:83–91.
22. Budowle B, Allard MW, Wilson MR. Critique of interpretation of high levels of heteroplasmy in the human mitochondrial DNA hypervariable region I from hair. *Forensic Sci Int* 2002;126:30–3.
23. Nagley P, Wei YH. Ageing and mammalian mitochondrial genetics. *Trends Genet* 1998;14(12):513–7.
24. Wallace DC. Mitochondrial diseases in man and mouse. *Science* 1999;283:1482–8.
25. Chinnery PF, Taylor GA, Howell N, Brown DT, Parsons TJ, Turnbull DM. Point Mutations of the mtDNA control region in normal and neurodegenerative human brains. *Am J Hum Genet* 2001;68:529–32.
26. Rosenthal A, Charnock-Jones DS. New protocols for DNA sequencing with dye terminators. *DNA Seq* 1992;3:61–4.
27. Parker LT, Zakeri H, Deng Q, Spurgeon S, Kwok PY, Nickerson DA. AmpliTaq<sup>®</sup> DNA Polymerase, FS Dye-Terminator sequencing: analysis of peak height patterns. *Biotechniques* 1996;21:694–9.
28. Zakeri H, Amparo G, Chen SM, Spurgeon S, Kwok PY. Peak height pattern in dichloro-rhodamine and energy transfer dye terminator sequencing. *Biotechniques* 1998;25(3):406–14.
29. Korch C, Drabkin H. Improved DNA sequencing accuracy and detection of heterozygous alleles using manganese citrate and different fluorescent dye terminators. *Genome Res* 1999;9:588–95.
30. Tully LA, Parsons TJ, Steighner RJ, Holland MM, Marino MA, Prenger VL. A sensitive denaturing gradient-gel electrophoresis assay reveals a high frequency in hypervariable region 1 of the human mtDNA control region. *Am J Hum Genet* 2000;67:432–43.
31. Hancock DK, Tully LA, Levin BC. A standard reference material to determine the sensitivity of techniques for detecting low-frequency mutations, SNPs, and heteroplasmies in mitochondrial DNA. *Genomics* 2005;86:446–61.
32. Murdock DG, Wallace DC. PNA-mediated PCR clamping. In: Nielsen PE, editor. *Methods in molecular biology*, Vol 208: peptide nucleic acids: methods and protocols. Totowa NJ: Humana Press Inc, 2003: 145–64.
33. Elghom M, Buchardt O, Christensen L, Behrens C, Freier SM, Driver DA, et al. PNA hybridizes to complementary oligonucleotides obeying the Watson–Crick hydrogen bonding rules. *Nature* 1993;365:556–68.
34. Wilhem J, Pingoud A, Hahn M. Comparison between Taq DNA polymerase and its Stoffel fragment for quantitative real-time PCR with hybridisation probes. *Biotechniques* 2001;30:1052–62.
35. Von Wurmb-Schwark N, Higuchi R, Fenech AP, Elfstroem C, Meissner C, Oehmichen M, et al. Quantification of human mitochondrial DNA in a real time PCR. *Forensic Sci Int* 2002;126:34–9.

Additional information and reprint requests:  
 Catherine Thèves, Ph.D.  
 INSERM  
 U563 Bat C  
 Purpan University Hospital  
 Place du Dr Baylac  
 31059 Toulouse  
 France  
 E-mail: Catherine.Theves@toulouse.inserm.fr